Ocugen, Inc. (BMV:OCGN)

Market Cap	7.59B
Revenue (ttm)	98.50M
Net Income (ttm)	-1.17B
Shares Out	n/a
EPS (ttm)	-3.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,208
Average Volume	645
Open	25.50
Previous Close	25.26
Day's Range	25.10 - 25.50
52-Week Range	11.00 - 35.64
Beta	n/a
RSI	47.78
Earnings Date	Mar 2, 2026

About Ocugen

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 95
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: OCGN

Financial Performance

In 2024, Ocugen's revenue was $4.06 million, a decrease of -32.82% compared to the previous year's $6.04 million. Losses were -$54.05 million, -14.31% less than in 2023.

Financial numbers in USD